In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sawai Pharmaceutical Co., Ltd.

Latest From Sawai Pharmaceutical Co., Ltd.

What’s Next? Five Things To Look Out For In August

Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.

Sales & Earnings Generic Drugs

Sawai Chalks Up More Than A Dozen Launches

Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.

Launches Generic Drugs

Japan’s Sawai Forecasts Sales Milestone This Year

Sales growth through new product launches and increasing the value of its current portfolio will allow Sawai to increase sales by around a tenth this year, the Japanese firm has forecasted, as it also revealed full-year financials for the 12 months ended 31 March 2020.

Sales & Earnings Strategy

Sawai Receives A Host Of Japanese Approvals

Sawai has received a raft of generics approvals from Japan’s Ministry of Health, Labour and Welfare, including approval for a tadalafil rival to Cialis and 10 first-time generic approvals.

Approvals Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Cambridge Biotechnology Ltd (CBT)
    • Minster Pharmaceuticals
    • Proximagen Group
    • Upsher-Smith Laboratories Inc.
    • Medisa Shinyaku Inc. and Kaken Shoyaku Inc.